

RESEARCH ARTICLE

# Two Independent Mutations in *ADAMTS17* Are Associated with Primary Open Angle Glaucoma in the Basset Hound and Basset Fauve de Bretagne Breeds of Dog

James A. C. Oliver\*, Oliver P. Forman, Louise Pettitt, Cathryn S. Mellersh

Department of Canine Genetics Research, Centre for Preventive Medicine, Animal Health Trust, Newmarket, Suffolk, United Kingdom

\* [James.Oliver@ah.org.uk](mailto:James.Oliver@ah.org.uk)



OPEN ACCESS

**Citation:** Oliver JAC, Forman OP, Pettitt L, Mellersh CS (2015) Two Independent Mutations in *ADAMTS17* Are Associated with Primary Open Angle Glaucoma in the Basset Hound and Basset Fauve de Bretagne Breeds of Dog. PLoS ONE 10(10): e0140436. doi:10.1371/journal.pone.0140436

**Editor:** Ted S Acott, Casey Eye Institute, UNITED STATES

**Received:** July 23, 2015

**Accepted:** September 25, 2015

**Published:** October 16, 2015

**Copyright:** © 2015 Oliver et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** No specific funding from external funding bodies was used to support this investigation. A DNA test has been developed, based on our findings, and is being offered commercially by the Animal Health Trust (AHT) as an aide to breeders to reduce the prevalence of POAG in the Basset Hound. The AHT is a registered charity (Registered Charity No: 209642) and a non-profit organisation and as such any profit from the sale of DNA tests will be re-

## Abstract

### Purpose

Mutations in *ADAMTS10* (CFA20) have previously been associated with primary open angle glaucoma (POAG) in the Beagle and Norwegian Elkhound. The closely related gene, *ADAMTS17*, has also been associated with several different ocular phenotypes in multiple breeds of dog, including primary lens luxation and POAG. We investigated *ADAMTS17* as a candidate gene for POAG in the Basset Hound and Basset Fauve de Bretagne dog breeds.

### Methods

We performed *ADAMTS17* exon resequencing in three Basset Hounds and three Basset Fauve de Bretagne dogs with POAG. Identified variants were genotyped in additional sample cohorts of both breeds and dogs of other breeds to confirm their association with disease.

### Results

All affected Basset Hounds were homozygous for a 19 bp deletion in exon 2 that alters the reading frame and is predicted to lead to a truncated protein. Fifty clinically unaffected Basset Hounds were genotyped for this mutation and all were either heterozygous or homozygous for the wild type allele. Genotyping of 223 Basset Hounds recruited for a different study revealed a mutation frequency of 0.081 and predicted frequency of affected dogs in the population to be 0.007. Based on the entire genotyping dataset the association statistic for the POAG-associated deletion was  $p = 1.26 \times 10^{-10}$ . All affected Basset Fauve de Bretagne dogs were homozygous for a missense mutation in exon 11 causing a glycine to serine amino acid substitution (G519S) in the disintegrin-like domain of *ADAMTS17* which is predicted to alter protein function. Unaffected Basset Fauve de Bretagne dogs were either heterozygous for the mutation (5/24) or homozygous for the wild type allele (19/24). Based on the entire genotyping dataset the association statistic for the POAG-associated deletion

invested in our canine genetics research, in line with our charitable objectives.

**Competing Interests:** The authors have declared that no competing interests exist.

was  $p = 2.80 \times 10^{-7}$ . Genotyping of 85 dogs of unrelated breeds and 90 dogs of related breeds for this variant was negative.

## Conclusion

This report documents strong associations between two independent *ADAMTS17* mutations and POAG in two different dog breeds.

## Introduction

Glaucoma is a heterogeneous disease which is usually associated with defects within the trabecular meshwork (TM) and anterior chamber which lead to obstruction of aqueous humour outflow, elevation of intraocular pressure (IOP) and progressive retinal ganglion cell death and optic nerve degeneration. In humans, glaucoma is the most common cause of irreversible blindness worldwide [1]. Glaucoma is described as primary if it occurs in the absence of any antecedent ocular disease and secondary if it occurs as a result of a concurrent observable ocular condition. Primary glaucoma can be further classified into primary open angle glaucoma (POAG) and primary closed angle glaucoma (PCAG) on the basis of the appearance of the iridocorneal angle. POAG is the more common form of primary glaucoma in man, will affect 58.9 million people by 2020 and is typically characterised by adult onset and chronic IOP-dependent progression [1,2].

In man, a number of studies have indicated the familial nature of POAG and support the role of genetic factors in its pathogenesis [3–6]. POAG in man is generally considered to be a complex genetic disorder and a minority of POAG cases can be explained by mutations in single genes. That said, multiple families are known to be affected by Mendelian forms of POAG and linkage analyses have identified multiple loci which segregate with disease [7–9], leading to the identification of causal mutations within several genes including myocillin (*MYOC*), optineurin (*OPTN*) and WD repeat domain 36 (*WDR36*) [10–12].

In dogs, POAG is a relatively rare condition although its high prevalence in specific breeds suggests an inherited aetiology. Affected breeds include the Beagle and Norwegian Elkhound [13–17]. In both these breeds POAG is an autosomal recessive condition caused by two separate mutations in *ADAMTS10* [14–16]. Further research in the Beagle has shown that the *ADAMTS10* mutation responsible for POAG is also associated with an inherently weaker and biochemically distinct posterior sclera before clinical evidence of optic nerve damage becomes apparent [18]. Mutations in a closely related gene, *ADAMTS17*, are responsible for primary lens luxation in multiple dog breeds and POAG in the Petit Basset Griffon Vendeen [19–21]. In man, homozygous mutations in *ADAMTSL4*, *ADAMTS10*, *ADAMTS17* cause various ocular phenotypes including ectopia lentis, myopia and glaucoma [22–24]. Furthermore, *ADAMTS4* has been shown to be important in aqueous humour outflow in human and porcine eyes [25]. These studies suggest that the *ADAMTS* and *ADAMTSL* gene families play an important role in ocular function and demonstrate how mutations within the same gene can cause multiple ocular phenotypes. In this manuscript, we report our investigation of *ADAMTS17* as a candidate gene for POAG in two additional dog breeds—the Basset Hound and Basset Fauve de Bretagne.

## Materials and Methods

### Sample Collection and Nucleic Acid Extraction

All experiments were conducted in accordance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and approved by the Animal Health Trust's Research and Ethical Approval Committee. All dogs were pets and ophthalmological examination and buccal mucosal swabbing were only performed after informed and written owner consent.

226 Basset Hounds and 27 Basset Fauve de Bretagne dogs underwent ophthalmic examination by a board-certified veterinary ophthalmologist which included slit-lamp biomicroscopy, direct and indirect ophthalmoscopy, rebound tonometry and gonioscopy. These examinations are non-painful and non-invasive. Gonioscopy was performed only following application of topical anaesthetic to ensure no breach of animal welfare. All Basset Hounds were recruited for examination for a separate study and were believed by the owners to be free from clinical ophthalmic disease at the time of examination. These dogs were examined at different events and locations across the United Kingdom to ensure as representative a cross-section of the breed population was sampled as possible. No attempt was made to target Basset Hounds of any particular lineage; all dogs that were volunteered by their owners were examined and included in the study, regardless of their sex, age or pedigree. Affected Basset Fauve de Bretagne dogs presented as clinical cases whereas the unaffected dogs of this breed were recruited to screen for evidence of POAG.

POAG was diagnosed in 3 Basset Hound (2 males, 1 female) and 3 Basset Fauve de Bretagne dogs (1 male, 2 females). All affected dogs had different owners and resided in different locations and, at the time of sampling, were not known to be generally related. The mean age ( $\pm$ SD) of the POAG affected dogs was  $49.33\pm 5.44$  months (Basset Hounds) and  $68.33\pm 12.66$  months (Basset Fauve de Bretagnes). Inclusion criteria for dogs with POAG were; absence of an identifiable cause of secondary glaucoma, open iridocorneal angles on gonioscopy, elevated IOP ( $>25$ mmHg), buphthalmos and lens subluxation. 223 Basset Hound and 24 Basset Fauve de Bretagne dogs were found to be free from all clinical signs of POAG. The 223 clinically unaffected Basset Hounds had a mean age of  $51.96\pm 2.61$  months and 85 (38%) were male and 138 (62%) were female. The 24 clinically unaffected Basset Fauve de Bretagnes had a mean age of  $124.38\pm 78.1$  months and 12 (50%) were male and 12 (50%) were female. DNA was extracted from buccal mucosal swabs from each dog using the QIAmp<sup>®</sup> DNA blood Midi Kit (Qiagen, Manchester, UK) according to manufacturer's instructions.

### *ADAMTS10* Candidate Variant Genotyping

All POAG-affected Basset Hounds and Basset Fauve de Bretagne dogs were genotyped for the two previously published canine POAG-associated variants using primers and thermal cycling parameters as previously described [14,16]. Sanger sequencing methodology, was used with Bigdye v3.1 chemistry (Life Technologies Ltd, Paisley, UK). Sequencing products were separated on an ABI3130xl genetic analyser and data analysed using the Staden Gap4 software package (<http://staden.sourceforge.net/>).

### *ADAMTS17* Resequencing

Primer pairs were designed to amplify the coding sequence and flanking splices sites for all 23 canine *ADAMTS17* exons using gene sequences derived from the Ensembl genome browser (<http://www.ensembl.org/index.html>) (S1 Table). Resequencing of the exons was performed after PCR amplification of genomic DNA in all POAG cases. PCRs were carried out in 12  $\mu$ l reactions consisting of 0.6 U Qiagen HotStarTaq DNA polymerase and 1 x PCR buffer

(Qiagen, Manchester, UK), 200  $\mu$ M dNTPs (Fisher Scientific—UK Ltd, Loughborough, UK), 0.83  $\mu$ M forward and reverse primer (Integrated DNA Technologies, Leuven, Belgium) and 10 ng template genomic DNA. The Qiagen Q solution additive (1 x) was used for GC rich amplicons (exons 1 & 2) (Qiagen, Manchester, UK). Reaction mixtures were subjected to a thermal cycling program of 95°C for 10 min, followed by 35 cycles of 95°C for 30 s, 30 s at the annealing temperature ([S1 Table](#)) and 72°C for 1 min and a final elongation stage of 72°C for 10 min. *ADAMTS17* exome libraries for Illumina sequencing were made using the Nextera XT DNA Library Preparation Kit as per the manufacturer's instructions (Illumina, San Diego, USA). Sequencing of all POAG cases was performed on the Illumina MiSeq platform, generating a dataset of 75 bp paired-end reads. Next generation sequencing results were confirmed for all POAG cases by Sanger sequencing.

## Sequencing Data Analysis

Sequence reads were aligned to the canine reference genome assembly (CanFam3.1) using the Burrows-Wheeler Alignment tool (BWA) [26]. Read alignments were visualised using the Integrated Genome Viewer and the data manually browsed for variants [27]. The potential pathogenicity of non-synonymous variants was tested with the SIFT bioinformatics tool [28]. Sanger sequencing results were analysed using the Staden Gap4 software package (<http://staden.sourceforge.net/>).

## Genotyping of the *ADAMTS17* Candidate Causal Variants

Candidate causal variants were genotyped using either a fragment length analysis or Sanger sequencing approach. Primer pairs were designed to amplify the candidate causal variants using gene sequences derived from the UCSC bioinformatics site (<https://genome.ucsc.edu/>) ([S2 Table](#)). For the Basset Hound, 12  $\mu$ L PCR reactions consisted of 0.5 U Qiagen HotStarTaq DNA polymerase, 1 x Qiagen PCR buffer and 1 x Qiagen Q solution (Qiagen, Manchester, UK), 200  $\mu$ M dNTPs (Fisher Scientific—UK Ltd, Loughborough, UK), 0.4  $\mu$ M forward and reverse primer (Integrated DNA Technologies, Leuven, Belgium) and 10 ng template genomic DNA. Reaction mixtures were subjected to a thermal cycling program of 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 30 s at an annealing temperature of 60°C ([Table 1](#)) and 72°C for 30 s and a final elongation stage of 72°C for 30 min. For the Basset Fauve de Bretagne dogs the 12  $\mu$ L reactions consisted of 0.25 U Qiagen HotStarTaq DNA polymerase and 1 x Qiagen PCR buffer (Qiagen, Manchester, UK), 200  $\mu$ M dNTPs (Fisher Scientific—UK Ltd, Loughborough, UK), 0.83  $\mu$ M forward and reverse primer (Integrated DNA Technologies, Leuven, Belgium) and 10 ng template genomic DNA. Reaction mixtures were subjected to a thermal cycling program of 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 57°C for 30 s and 72°C for 30 s and a final elongation stage of 72°C for 5 min. Basset Hounds were genotyped for the 19 bp deletion using capillary electrophoresis of 5' 6FAM labelled PCR products on ABI3130xl genetic analysers, and data scored using GeneMapper v4.0 (Life Technologies Ltd, Paisley, UK). Basset Fauve de Bretagne dogs were genotyped for the candidate SNP using a standard Sanger sequencing methodology, using Bigdye v3.1 chemistry (Life Technologies Ltd, Paisley, UK). Sequencing products were separated on an ABI3130xl genetic analyser and data analysed using the Staden Gap4 software package (<http://staden.sourceforge.net/>). Additional genotyping and verification of the Sanger sequencing results was performed using a TaqMan allelic discrimination approach (Life Technologies, Paisley, UK) [29]. Primer details are provided in [S3 Table](#). Reactions were carried out in 8  $\mu$ L volumes consisting of 4  $\mu$ L Kapa probe fast (Kapa Biosystems), 0.2  $\mu$ L 40x probe mix, 2  $\mu$ L genomic DNA and 1.8  $\mu$ L ultrapure water. Cycling parameters were 40 cycles of 95°C for 3 s and 60°C for 15 s. Primer and probe

**Table 1. Published mutations and their phenotypes in canine and human *ADAMTS17*.**

Species (breed or ethnicity)	Ocular Phenotype	Systemic Phenotype	Exon/ intron	Mutation	Nature of mutation	State of zygosity	Reference
Man (Saudi Arabian)	Lenticular myopia, ectopia lentis, spherophakia, glaucoma	Short stature	Exon 18	c.2458_2459insG	Frameshift	Homozygous	
Man (Saudi Arabian)	Lenticular myopia, ectopia lentis, spherophakia	Short stature, brachydactyly, joint stiffness	Intron 12	c.1721+1G>A	Splice site	Homozygous	[22]
Man (Saudi Arabian)	Lenticular myopia, ectopia lentis, spherophakia,	Short stature	Exon 4	c.760C>T	Nonsense	Homozygous	[22]
Man (Saudi Arabian)	Spherophakia	Short stature	Exon 4	c.652delG	Frameshift	Homozygous	[41]
Man (Tunisian)	Microspherophakia, myopia	Short stature, congenital ichthyosis	Exon 1–3	106.96 Kb deletion	Deletion	Homozygous	[42]
Man (Indian)	Microspherophakia	Short stature, brachydactyly	Intron 5	c.873+1G>T	Splice site	Homozygous	[23]
Dog (multiple breeds)	Primary lens luxation	None	Intron 10	GT>AT	Splice site	Homozygous	[19]
Dog (Petit Basset Griffon Vendéen)	POAG	None	Intron 12	Large scale genetic rearrangement	Inversion	Homozygous	[21]
Dog (Basset Hound)	POAG	None	Exon 2	19 bp deletion	Deletion	Homozygous	Present study
Dog (Basset Fauve de Bretagne)	POAG	None	Exon 11	c.1552G>A	Missense	Homozygous	Present study

doi:10.1371/journal.pone.0140436.t001

sequences are listed in [S3 Table](#). Mutant allele frequencies were calculated and the frequency of affected dogs calculated assuming the alleles were in Hardy-Weinberg equilibrium within the population. Based on the entire genotyping data set for each breed, POAG-associated association statistics for candidate variants were calculated using PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/anal.shtml>).

## Results

### *ADAMTS10* genotyping

All POAG-affected Basset Hounds and Basset Fauve de Bretagne dogs were homozygous for the wild type alleles at the chromosomal locations of both previously published POAG-associated variants.

### *ADAMTS17* Resequencing

**Basset Hound.** Visual scanning of the sequence read alignments from clinically affected Basset Hounds revealed only one variant that segregated with disease in the three affected dogs. This variant was a homozygous 19 bp deletion in exon 2 of *ADAMTS17* (CanFam3.1 chr3:40,614,853–40,614,872, [Fig 1a](#)) and was confirmed by Sanger sequencing ([Fig 1b](#)). The deletion is predicted to alter the reading frame of the gene, leading to 87 aberrant amino acids before introducing a premature stop codon at the 5' end of exon 3, a predicted truncation of 86.1% of the protein ([Fig 2](#)). Fifty clinically unaffected Basset Hounds over the age of 72 months (controls) were genotyped for this allele; all were homozygous for the wild type.




DNA (clear)	181	AAGCGCCGGCGC	CCCCGCGCGCCCTCGGGC	CCCCGCGCGCCCGGCCGGCGAGCGCGCC
Protein (clear)	61	-K--R--R--R--P--R--A--P--L--G--A--P--R--A--R--P--G--E--R--A--		
DNA (clear)	241	CTGCTGCTGCACCTGCCGGCCTTTGGGCGCGACCTGTACCTGCAGCTTCGCCACGACCTG		
Protein (clear)	81	-L--L--L--H--L--P--A--F--G--R--D--L--Y--L--Q--L--R--H--D--L--		
DNA (clear)	301	CGCTTCCTGTCCCGCGGCTTCGAGGTGGAGGAGGCGGGCGCGGCCGGGCGCCGGACGG		
Protein (clear)	101	-R--F--L--S--R--G--F--E--V--E--E--A--G--A--A--G--R--R--G--R--		
DNA (clear)	361	CCCGCCGAGCTGTGCTTCTACTCGGGCCGCGTGTCTCGGCCACCCGGGCTCCCTCGTCTCG		
Protein (clear)	121	-P--A--E--L--C--F--Y--S--G--R--V--L--G--H--P--G--S--L--V--S--		
DNA (clear)	421	CTCAGCGCCTGCGGCGCCGGCGGGCGGCCTGGTTGGCCTCATCCAGCTTGGGCAGGAACAG		
Protein (clear)	141	-L--S--A--C--G--A--G--G--G--L--V--G--L--I--Q--L--G--Q--E--Q--		
		↓		
DNA (affected)	181	AAGCGCCGGCGC	CCCCGCGCGCCCGGCCGGCGAGCGCGCCCTGCTGCTGCACCTGCCGG	
Protein (affected)	61	-K--R--R--R--P--R--A--P--G--P--A--S--A--A--L--L--C--T--C--R--		
DNA (affected)	241	CCTTTGGGCGCGACCTGTACCTGCAGCTTCGCCACGACCTGCGCTTCCTGTTC		
Protein (affected)	81	<u>-P--L--G--A--T--C--T--C--S--F--A--T--T--C--A--S--C--P--A--A--</u>		
DNA (affected)	301	TCGAGGTGGAGGAGGCGGGCGGGCCGGGCGCCGGACGGCCCGGAGCTGTGCTTCT		
Protein (affected)	101	<u>-S--R--W--R--R--R--A--R--P--G--A--A--N--G--P--P--S--C--A--S--</u>		
DNA (affected)	361	ACTCGGGCCGCGTGTCTCGGCCACCCGGGCTCCCTCGTCTCGCTCAGCGCCTGCGGCGCCG		
Protein (affected)	121	<u>-T--R--A--A--C--S--G--H--P--G--L--P--R--L--A--Q--R--L--R--A--P--</u>		
DNA (affected)	421	GCGGCGGCCTGGTTGGCCTCATCCAGCTTGGGCAGGAACAGGTGC	TAA	
Protein (affected)	141	<u>-A--A--A--W--L--A--S--S--S--L--G--R--N--R--C--</u>	STP	

**Fig 2. DNA and corresponding protein sequences in a normal Basset Hound (top) and one with POAG (bottom).** The position of the deletion is indicated with a black arrow and the 19 deleted bases are indicated by shading in the DNA sequence of the clear dog. The deletion generates a frame shift leading to 87 aberrant amino acids (underlined) which introduces a premature stop codon, indicated by shading in the POAG-affected dog.

doi:10.1371/journal.pone.0140436.g002

Genotyping of 173 additional Basset Hounds recruited for a different study and also known to be free of clinical signs of POAG, revealed 137 were homozygous for the wild type allele and 36 were heterozygous for the mutation. The frequency of the deletion in this subset of 223 Basset hounds was therefore 0.081 and the predicted frequency of affected dogs in the population estimated to be 0.007. One hundred and fifty two dogs of unrelated breeds (mixed breed panel) were all homozygous for the wild type allele. Following identification of this mutation, the owners of all affected dogs were contacted and pedigrees were obtained and reviewed. Analysis of these revealed two of the affected dogs to be full siblings although the third affected dog shared no common ancestors in its five generation pedigree. Taking into account the presence of the two full siblings, the association statistic between the deletion and POAG based on the entire genotyping dataset was  $p = 1.26 \times 10^{-10}$ .

**Basset Fauve de Bretagne.** Visual scanning of the sequence read alignments from clinically affected Basset Fauve de Bretagne dogs revealed only one variant that segregated with disease—a homozygous G>A substitution in exon 11 of *ADAMTS17* (CanFam3.1



**Fig 3. Electropherograms depicting the site of the missense mutation in the Basset Fauve de Bretagne affected with POAG.** The red box depicts the exact site of the mutation (CanFam3.1 chr3:40,808,345). At this location, the wild type is GG, the carrier is AG and the POAG case is GG.


doi:10.1371/journal.pone.0140436.g003

chr3:40,808,345, Fig 3). All affected Basset Fauve de Bretagne dogs were homozygous for this non-synonymous SNP which causes a glycine to serine (G519S) amino acid change in the disintegrin-like domain of *ADAMTS17* and is predicted to be deleterious by SIFT [30]. Sequencing of 24 clinically unaffected Basset Fauve de Bretagne dogs revealed five were heterozygous for the mutation and 19 were homozygous for the wild type allele. The association statistic of the variant with POAG based on the entire genotyping dataset was  $p = 2.80 \times 10^{-7}$ . Genotyping of 85 dogs of unrelated breeds (mixed breed panel) and 90 dogs of related breeds (Basset Hound, Wire Haired Dachshund, Petit Basset Griffon Vendéen, Grande Basset Griffon Vendéen) for this variant with a TaqMan allelic assay revealed them all to be homozygous for the wild type allele.

## Discussion

Our study investigated *ADAMTS17* as a candidate gene for POAG in two different dog breeds—the Basset Hound and Basset Fauve de Bretagne. We considered *ADAMTS17* to be a strong candidate gene for study for several reasons. Firstly, a different mutation in *ADAMTS17* has recently been reported to cause POAG in another dog breed—the Petit Basset Griffon Vendéen [21]. Secondly, another *ADAMTS17* mutation is known to cause another canine ocular phenotype, primary lens luxation, which is characterised by structural abnormalities and weakness of the lens zonular fibres with ultimate dislocation of the lens from the patellar fossa (Table 1) [19,20]. The ciliary body is not only the site of origin of the lens zonular fibres and involved in their ongoing maintenance but it also contributes to IOP. The ciliary body is both responsible for aqueous humour production and also forms the ciliary cleft via which aqueous humour is drained from the eye into the systemic circulation. It is also already known that *ADAMTS17* is





**Fig 4. *ADAMTS17* protein structure denoting amino acid positions of the Basset Hound and Basset Fauve de Bretagne POAG mutations.** ADAMTS17 is composed of a signal peptide (SP), prodomain (PRO), catalytic domain (CAT) (composed of the metalloproteinase (MP) and disintegrin-like domains (DL)) and an ancillary domain (ANC). The Basset Hound deletion corresponds to amino acid position 65 which is located in PRO. The Basset Fauve de Bretagne mutation corresponds to amino acid position 519 which is located in DL. Adapted from Kelwick et al. [31]

doi:10.1371/journal.pone.0140436.g004

expressed within the ciliary body [19]. Thus, with consideration, it would not be surprising for different mutations within this gene to be associated with multiple intraocular phenotypes relating to abnormal function of the same anatomical region of the eye [19]. Thirdly, *ADAMTS17* mutations cause Weill-Marchesani and Weill-Marchesani-like syndromes in man [22,23]. These syndromes are rare connective tissue disorders which are characterised by various intraocular phenotypes including ectopia lentis, spherophakia, myopia and glaucoma along with joint stiffness and brachydactyly (Table 1). Clinical and genetic studies of these diseases suggest that *ADAMTS17* also plays a role in lens zonules and connective tissue formation in man [22,23]. Finally, mutations in closely related genes, *ADAMTS10* and *ADAMTSL4*, are known to be involved in primary glaucoma and other ocular connective tissue disorders in both man and dog [14–16,18,22,24,25].

In the Basset Hound, a homozygous 19 bp deletion in exon 2 was present in all POAG-affected dogs. The deletion is predicted to alter the reading frame of the transcript and introduce a premature stop codon at the 5' end of exon 3, which would result in a truncated and aberrant protein if the RNA is stable and not subjected to nonsense-mediated decay (Fig 2). If the transcript is translated the protein is expected to be truncated by 86.1% which would include the entire catalytic domain which is expected to lead to complete loss of protein function (Fig 4). Further supportive evidence for the deletion as the causative mutation of POAG in the Basset Hound was derived from genotyping. Our genotyping cohort included 223 Basset Hounds which had undergone complete ophthalmic examination and were found to be free from clinical signs of POAG at the time. 50 of these were significantly older than the POAG cases and were thought to be at very low risk of developing POAG in the future. These dogs served as controls and none were found to be homozygous for the identified mutation. Genotyping of the entire cohort allowed calculation of carrier frequency within the breed within the United Kingdom. These dogs were all resident and distributed widely around the United Kingdom and DNA had been collected from them for a parallel study. They can therefore be

considered a random cohort with respect to the current study and representative of the Basset Hound population in the UK. The frequency of the mutant allele (0.081) and expected frequency of dogs affected with POAG (0.007) are fairly high. These data, together with the fact that POAG is a painful and blinding condition, underpin the importance of this mutation. With this in mind, a DNA test has been developed to allow Basset Hound breeders to genotype their dogs prior to breeding.

The variant we have identified that is associated with POAG in the Basset Fauve de Bretagne is a non-synonymous SNP that results in a glycine to serine amino acid change in the disintegrin-like domain of the protein which is essential for the catalytic function of the protein [31] (Fig 4). Glycine is a highly conserved residue within the disintegrin-like domain across the entire ADAMTS family and also across species (Figs 5 and 6), providing strong evidence that this SNP is causal for POAG in this breed. Furthermore, 85 dogs of unrelated breeds and 90 dogs of related breeds were all homozygous for the wild type allele indicating that this variant is not a common polymorphism within the wider canine population.

ADAMTS17 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs) is a member of a family of 19 known mammalian zinc-dependent metalloproteinases. Like other matrix metalloproteinases (MMPs), ADAMTSs have a role in extracellular matrix (ECM) degradation and turnover as well as in proteolysis of cell surface and soluble proteins [30, 31]. All ADAMTSs are secreted, extracellular enzymes that have a compound domain organisation comprising, from the amino terminus: a signal peptide followed by a pro-domain; a catalytic domain; and an ancillary domain that contains one or more thrombospondin type 1 repeats [31,32] (Fig 4). The pro-domain, amongst other functions, maintains latency and direct proper folding of the enzyme. The catalytic domain is comprised of metalloproteinase and disintegrin-like modules and confers the protease activity of the protein. The ancillary domain determines substrate specificity, localisation of the protease and its interaction partners [23,31,32]. ADAMTS-like genes (*ADAMTSL*) encode proteins that resemble the ancillary domains of ADAMTS but lack their catalytic domains and it is thought that these proteins may modulate the activities of the ADAMTSs [32,33].

The exact functions of ADAMTSs and ADAMTSLs are unknown. There is, however, strong support of a functional association between ADAMTS proteins and fibrillin microfibrils. Mutations in *ADAMTS10*, *ADAMTS17* and *ADAMTSL4* result in phenotypes that resemble those caused by mutations in fibrillin-1 (FBN1) [22,24,34–36]. It is thus suggested that ADAMTS and ADAMTSL proteins are involved either in microfibril assembly, stability and anchorage or the formation of function-specific supramolecular networks having microfibrils as their foundation [37]. How this functional relationship might be involved in POAG is unclear. The ECM of the TM is thought to be important in regulating intraocular pressure (IOP) [38]. In response to elevated IOP, specific proteases including MMPs are thought to be released by TM cells and are activated to degrade selected ECM molecules, leading to decreased resistance to aqueous humour outflow [39,40]. Furthermore, ADAMTS4 mRNA levels increase in response to increased IOP and recombinant ADAMTS4 increase outflow facility in human and porcine anterior segments [25]. Thus, loss of function mutations in genes which encode the proteins involved in ECM degradation are likely to be associated with elevated IOP and glaucoma. Further work, however, is required to determine if ADAMTS17 is indeed one of these proteins and to further understand POAG pathogenesis.

In conclusion, we report two separate mutations in *ADAMTS17* that are both strongly associated with the same ocular phenotype, POAG, in two different dog breeds. This report provides further evidence of the importance of *ADAMTS17* in intraocular physiology and increases the total number of reported canine *ADAMTS17* mutations to four (Table 1).

<b>ADAMTS1</b>	<b>Pro-Trp-Ala-Asp-Gly-Thr-Ser-Cys-Gly</b>
<b>ADAMTS2</b>	<b>Pro-Pro-Leu-Asp-Gly-Thr-Met-Cys-Ala</b>
<b>ADAMTS3</b>	<b>Pro-Pro-Leu-Asp-Gly-Thr-Met-Cys-Ala</b>
<b>ADAMTS4</b>	<b>Pro-Trp-Ala-Asp-Gly-Thr-Pro-Cys-Gly</b>
<b>ADAMTS5</b>	<b>Pro-Ala-Val-Glu-Gly-Thr-Pro-Cys-Gly</b>
<b>ADAMTS6</b>	<b>Pro-Ala-Ala-Glu-Gly-Thr-Leu-Cys-Gln</b>
<b>ADAMTS7</b>	<b>Ala-Ala-Val-Asp-Gly-Thr-Atg-Cys-Gly</b>
<b>ADAMTS8</b>	<b>Pro-Trp-Ala-Asp-Gly-Thr-Glu-Cys-Gly</b>
<b>ADAMTS9</b>	<b>Pro-Trp-Ala-Asp-Gly-Thr-Glu-Cys-Glu</b>
<b>ADAMTS10</b>	<b>Pro-Ala-Ala-Glu-Gly-Thr-Leu-Cys-Gln</b>
<b>ADAMTS12</b>	<b>Ala-Ala-Ala-Asp-Gly-Thr-Gln-Cys-Gly</b>
<b>ADAMTS13</b>	<b>Pro-Leu-Leu-Asp-Gly-Thr-Glu-Cys-Gly</b>
<b>ADAMTS14</b>	<b>Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Ala</b>
<b>ADAMTS15</b>	<b>Pro-Trp-Ala-Asp-Gly-Thr-Ser-Cys-Gly</b>
<b>ADAMTS16</b>	<b>Pro-Ala-Ala-Glu-Gly-Thr-Ile-Cys-Gly</b>
<b>ADAMTS17</b>	<b>Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly</b>
<b>ADAMTS18</b>	<b>Pro-Ala-Ala-Glu-Gly-Thr-Val-Cys-Gly</b>
<b>ADAMTS19</b>	<b>Pro-Pro-Met-Asp-Gly-Thr-Asp-Cys-Asp</b>
<b>ADAMTS20</b>	<b>Pro-Pro-Ala-Asp-Gly-Thr-Asp-Cys-Gly</b>

**Fig 5. A selected region of the amino acid sequence of the disintegrin-like domain in the entire *ADAMTS* family.** The region is centred on the glycine residue (in red) which is highly conserved and is the site of the missense mutation in the Basset Fauve de Bretagne.

doi:10.1371/journal.pone.0140436.g005

Dog	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Panda	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Ferret	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Cat	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Horse	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Microbat	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Megabat	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Cow	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Sheep	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Dolphin	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Alpaca	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Guinea Pig	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Kangaroo Rat	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Mouse	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Rat	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Squirrel	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Rabbit	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Vervet-AGM	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Macaque	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Gorilla	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Human	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Chimpanzee	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Gibbon	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Tarsier	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Mouse Lemur	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Bushbaby	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Sloth	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Armadillo	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Lesser Hedgehog Tenrec	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala
Hyrax	Asp-Pro-Pro-Leu-Asp-Gly-Thr-Glu-Cys-Gly-Ala

**Fig 6. A selected region of the amino acid sequence of the disintegrin-like domain in *ADAMTS17* in 31 species.** The region is centred on the glycine residue (in red) which is highly conserved and is the site of the missense mutation in the Basset Fauve de Bretagne.

doi:10.1371/journal.pone.0140436.g006

## Supporting Information

S1 Table. PCR Primers for *ADAMTS17* Resequencing.

(PDF)

S2 Table. Primer pairs for amplification of candidate causal variants in *ADAMTS17*.

(PDF)

S3 Table. Allelic discrimination primers and probes.

(PDF)

## Author Contributions

Conceived and designed the experiments: JO OF LP CM. Performed the experiments: JO OF LP. Analyzed the data: JO OF. Contributed reagents/materials/analysis tools: JO OF LP. Wrote the paper: JO OF CM.

## References

1. Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 90: 262–267. PMID: [16488940](#)
2. Takamoto M, Araie M (2014) Genetics of primary open angle glaucoma. *Jpn J Ophthalmol* 58: 1–15. doi: [10.1007/s10384-013-0286-0](#) PMID: [24258795](#)
3. Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, et al. (1998) Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. *Arch Ophthalmol* 116: 1640–1645. PMID: [9869795](#)
4. Teikari JM (1987) Genetic factors in open-angle (simple and capsular) glaucoma. A population-based twin study. *Acta Ophthalmol (Copenh)* 65: 715–720.
5. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, et al. (1991) Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *Jama* 266: 369–374. PMID: [2056646](#)
6. Racette L, Wilson MR, Zangwill LM, Weinreb RN, Sample PA (2003) Primary open-angle glaucoma in blacks: a review. *Surv Ophthalmol* 48: 295–313. PMID: [12745004](#)
7. Fan BJ, Wang DY, Lam DS, Pang CP (2006) Gene mapping for primary open angle glaucoma. *Clin Biochem* 39: 249–258. PMID: [16332362](#)
8. Baird PN, Foote SJ, Mackey DA, Craig J, Speed TP, et al. (2005) Evidence for a novel glaucoma locus at chromosome 3p21-22. *Hum Genet* 117: 249–257. PMID: [15906098](#)
9. Wiggs JL, Allingham RR, Hossain A, Kern J, Auguste J, et al. (2000) Genome-wide scan for adult onset primary open angle glaucoma. *Hum Mol Genet* 9: 1109–1117. PMID: [10767336](#)
10. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, et al. (1997) Identification of a gene that causes primary open angle glaucoma. *Science* 275: 668–670. PMID: [9005853](#)
11. Rezaie T, Child A, Hitchings R, Brice G, Miller L, et al. (2002) Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science* 295: 1077–1079. PMID: [11834836](#)
12. Monemi S, Spaeth G, DaSilva A, Popinchalk S, Ilitchev E, et al. (2005) Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. *Hum Mol Genet* 14: 725–733. PMID: [15677485](#)
13. Kato K, Sasaki N, Gelatt KN, Mackay EO, Shastry BS (2009) Autosomal recessive primary open angle glaucoma (POAG) in beagles is not associated with mutations in the myocilin (MYOC) gene. *Graefes Arch Clin Exp Ophthalmol* 247: 1435–1436. doi: [10.1007/s00417-009-1053-2](#) PMID: [19225800](#)
14. Kuchtey J, Kunkel J, Esson D, Sapienza JS, Ward DA, et al. (2013) Screening ADAMTS10 in dog populations supports Gly661Arg as the glaucoma-causing variant in beagles. *Invest Ophthalmol Vis Sci* 54: 1881–1886. doi: [10.1167/iovs.12-10796](#) PMID: [23422823](#)
15. Kuchtey J, Olson LM, Rinkoski T, Mackay EO, Iverson TM, et al. (2011) Mapping of the disease locus and identification of ADAMTS10 as a candidate gene in a canine model of primary open angle glaucoma. *PLoS Genet* 7: e1001306. doi: [10.1371/journal.pgen.1001306](#) PMID: [21379321](#)
16. Ahonen SJ, Kaukonen M, Nussdorfer FD, Harman CD, Komaromy AM, et al. (2014) A Novel Missense Mutation in ADAMTS10 in Norwegian Elkhound Primary Glaucoma. *PLoS One* 9: e111941. doi: [10.1371/journal.pone.0111941](#) PMID: [25372548](#)
17. Gelatt KN, Peiffer RL Jr, Gwin RM, Sauk JJ Jr (1976) Glaucoma in the beagle. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol* 81: Op636–644. PMID: [960386](#)
18. Palko JR, Iwabe S, Pan X, Agarwal G, Komaromy AM, et al. (2013) Biomechanical properties and correlation with collagen solubility profile in the posterior sclera of canine eyes with an ADAMTS10 mutation. *Invest Ophthalmol Vis Sci* 54: 2685–2695. doi: [10.1167/iovs.12-10621](#) PMID: [23518772](#)
19. Farias FH, Johnson GS, Taylor JF, Giuliano E, Katz ML, et al. (2010) An ADAMTS17 splice donor site mutation in dogs with primary lens luxation. *Invest Ophthalmol Vis Sci* 51: 4716–4721. doi: [10.1167/iovs.09-5142](#) PMID: [20375329](#)
20. Gould D, Pettitt L, McLaughlin B, Holmes N, Forman O, et al. (2011) ADAMTS17 mutation associated with primary lens luxation is widespread among breeds. *Vet Ophthalmol* 14: 378–384. doi: [10.1111/j.1463-5224.2011.00892.x](#) PMID: [22050825](#)
21. Forman O, Mellersh C (2015) Use of novel GWAS approaches and genome sequencing facilitates identification of large scale rearrangements associated with two inherited diseases. Abstract The 8th International Conference of Advances in Canine and Feline Genomics and Inherited Disease, Cambridge, UK.
22. Morales J, Al-Sharif L, Khalil DS, Shinwari JM, Bavi P, et al. (2009) Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. *Am J Hum Genet* 85: 558–568. doi: [10.1016/j.ajhg.2009.09.011](#) PMID: [19836009](#)

23. Shah MH, Bhat V, Shetty JS, Kumar A (2014) Whole exome sequencing identifies a novel splice-site mutation in *ADAMTS17* in an Indian family with Weill-Marchesani syndrome. *Mol Vis* 20: 790–796. PMID: [24940034](#)
24. Ahram D, Sato TS, Kohilan A, Tayeh M, Chen S, et al. (2009) A homozygous mutation in *ADAMTSL4* causes autosomal-recessive isolated ectopia lentis. *Am J Hum Genet* 84: 274–278. doi: [10.1016/j.ajhg.2009.01.007](#) PMID: [19200529](#)
25. Keller KE, Bradley JM, Acott TS (2009) Differential effects of *ADAMTS*-1, -4, and -5 in the trabecular meshwork. *Invest Ophthalmol Vis Sci* 50: 5769–5777. doi: [10.1167/iovs.09-3673](#) PMID: [19553617](#)
26. Peng X, Wang J, Zhang Z, Xiao Q, Li M, et al. (2015) Re-alignment of the unmapped reads with base quality score. *BMC Bioinformatics* 16 Suppl 5: S8. doi: [10.1186/1471-2105-16-S5-S8](#) PMID: [25860434](#)
27. Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 14: 178–192. doi: [10.1093/bib/bbs017](#) PMID: [22517427](#)
28. Grimm DG, Azencott CA, Aicheler F, Gieraths U, MacArthur DG, et al. (2015) The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity. *Hum Mutat* 36: 513–523. doi: [10.1002/humu.22768](#) PMID: [25684150](#)
29. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. *Genet Anal* 14: 143–149. PMID: [10084106](#)
30. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, et al. (2012) SIFT web server: predicting effects of amino acid substitutions on proteins. *Nucleic Acids Res* 40: W452–457. doi: [10.1093/nar/gks539](#) PMID: [22689647](#)
31. Kelwick R, Desanlis I, Wheeler GN, Edwards DR (2015) The *ADAMTS* (A Disintegrin and Metalloprotease with Thrombospondin motifs) family. *Genome Biol* 16: 113. doi: [10.1186/s13059-015-0676-3](#) PMID: [26025392](#)
32. Dubail J, Apte SS (2015) Insights on *ADAMTS* proteases and *ADAMTS*-like proteins from mammalian genetics. *Matrix Biol*.
33. Apte SS (2009) A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (*ADAMTS*) superfamily: functions and mechanisms. *J Biol Chem* 284: 31493–31497. doi: [10.1074/jbc.R109.052340](#) PMID: [19734141](#)
34. Chandra A, Aragon-Martin JA, Hughes K, Gati S, Reddy MA, et al. (2012) A genotype-phenotype comparison of *ADAMTSL4* and *FBN1* in isolated ectopia lentis. *Invest Ophthalmol Vis Sci* 53: 4889–4896. doi: [10.1167/iovs.12-9874](#) PMID: [22736615](#)
35. Greene VB, Stoetzel C, Pelletier V, Perdomo-Trujillo Y, Liebermann L, et al. (2010) Confirmation of *ADAMTSL4* mutations for autosomal recessive isolated bilateral ectopia lentis. *Ophthalmic Genet* 31: 47–51. doi: [10.3109/13816810903567604](#) PMID: [20141359](#)
36. Li J, Jia X, Li S, Fang S, Guo X (2014) Mutation survey of candidate genes in 40 Chinese patients with congenital ectopia lentis. *Mol Vis* 20: 1017–1024. PMID: [25053872](#)
37. Hubmacher D, Apte SS (2015) *ADAMTS* proteins as modulators of microfibril formation and function. *Matrix Biol*.
38. Acott TS, Kelley MJ (2008) Extracellular matrix in the trabecular meshwork. *Exp Eye Res* 86: 543–561. doi: [10.1016/j.exer.2008.01.013](#) PMID: [18313051](#)
39. Alexander JP, Samples JR, Van Buskirk EM, Acott TS (1991) Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. *Invest Ophthalmol Vis Sci* 32: 172–180. PMID: [1846130](#)
40. Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, et al. (1998) Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. *Invest Ophthalmol Vis Sci* 39: 2649–2658. PMID: [9856774](#)
41. Khan AO, Aldahmesh MA, Al-Ghadeer H, Mohamed JY, Alkuraya FS (2012) Familial spherophakia with short stature caused by a novel homozygous *ADAMTS17* mutation. *Ophthalmic Genet* 33: 235–239. doi: [10.3109/13816810.2012.666708](#) PMID: [22486325](#)
42. Radner FP, Marrakchi S, Kirchmeier P, Kim GJ, Ribierre F, et al. (2013) Mutations in *CERS3* cause autosomal recessive congenital ichthyosis in humans. *PLoS Genet* 9: e1003536. doi: [10.1371/journal.pgen.1003536](#) PMID: [23754960](#)